Press Releases April 30, 2026 04:05 PM

CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026

CapsoVision schedules Q1 2026 financial results release and conference call for May 14, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CV

CapsoVision, a commercial-stage medical technology company focused on advanced imaging and AI-enabled capsule endoscopy solutions, will release its Q1 2026 financial results on May 14, 2026, followed by a conference call and webcast to discuss performance and provide corporate updates.

CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
CV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CapsoVision specializes in AI-enabled capsule endoscopy for gastrointestinal disease detection and screening.
  • The company will announce Q1 2026 financial results and host a webcast conference call for investors.
  • CapsoVision's flagship product is CapsoCam Plus, a wire-free panoramic capsule endoscope with high resolution and cloud-based video retrieval, and it is developing CapsoCam Colon with enhanced AI for non-invasive colon imaging.

SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 5439091. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com

Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231


Risks

  • The release could reveal weaker-than-expected financial results impacting investor sentiment.
  • The company's future success depends on the adoption and regulatory approvals of its advanced imaging products.
  • Technological challenges and competition in the medical imaging and AI healthcare sector could affect growth prospects.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026